Tisotumab vedotin. Antibody-drug conjugate directed to tissue factor, Tubulin polymerization inhibitor, Treatment of solid tumors

G. D'Alessandro; F. Barra; A. Boutros; G. Evangelisti; L. Ferro Desideri; M. Moioli; S. Ferrero

doi:10.1358/dof.2020.45.10.3168441

Tisotumab vedotin. Antibody-drug conjugate directed to tissue factor, Tubulin polymerization inhibitor, Treatment of solid tumors

Drugs of the Future ◽

10.1358/dof.2020.45.10.3168441 ◽

2020 ◽

Vol 45 (10) ◽

pp. 717

Author(s):

G. D'Alessandro ◽

F. Barra ◽

A. Boutros ◽

G. Evangelisti ◽

L. Ferro Desideri ◽

...

Keyword(s):

Tissue Factor ◽

Solid Tumors ◽

Tubulin Polymerization ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Polymerization Inhibitor ◽

Tubulin Polymerization Inhibitor ◽

Inhibitor Treatment ◽

Antibody Drug

Download Full-text

An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

Cancer Research ◽

10.1158/0008-5472.can-13-2440 ◽

2013 ◽

Vol 74 (4) ◽

pp. 1214-1226 ◽

Cited By ~ 71

Author(s):

Esther C.W. Breij ◽

Bart E.C.G. de Goeij ◽

Sandra Verploegen ◽

Danita H. Schuurhuis ◽

Ali Amirkhosravi ◽

...

Keyword(s):

Tissue Factor ◽

Solid Tumors ◽

Therapeutic Activity ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

28LBA A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(16)31946-3 ◽

2015 ◽

Vol 51 ◽

pp. S724 ◽

Cited By ~ 2

Author(s):

A.W. Tolcher ◽

E. Calvo ◽

M.L. Maitland ◽

B. Gibson ◽

D. Xuan ◽

...

Keyword(s):

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors

Drugs of Today ◽

10.1358/dot.2019.55.9.3039669 ◽

2019 ◽

Vol 55 (9) ◽

pp. 575 ◽

Cited By ~ 3

Author(s):

K.M. Fenn ◽

K. Kalinsky

Keyword(s):

Breast Cancer ◽

Solid Tumors ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3757 ◽

2021 ◽

pp. clincanres.3757.2020

Author(s):

Michael L. Maitland ◽

Jasgit C Sachdev ◽

Manish R Sharma ◽

Victor Moreno ◽

Valentina Boni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Protein Tyrosine Kinase ◽

Human Study ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Protein Tyrosine ◽

Drug Conjugate ◽

Protein Tyrosine Kinase 7 ◽

Antibody Drug

Download Full-text

An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR

The Journal of Clinical Pharmacology ◽

10.1002/jcph.1418 ◽

2019 ◽

Cited By ~ 1

Author(s):

Rajendar K. Mittapalli ◽

Sven Stodtmann ◽

Anna Friedel ◽

Rajeev M. Menon ◽

Earle Bain ◽

...

Keyword(s):

Solid Tumors ◽

Population Pharmacokinetic Model ◽

Pharmacokinetic Model ◽

Population Pharmacokinetic ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Model Versus ◽

Antibody Drug ◽

Egfr Antibody

Download Full-text

Abstract 1197: Outstanding preclinical efficacy of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 in patient-derived xenograft solid tumors

10.1158/1538-7445.am2016-1197 ◽

2016 ◽

Cited By ~ 1

Author(s):

Loreley Calvet ◽

Anne-Marie Lefebvre ◽

Celine Nicolazzi ◽

Lydia Blot ◽

Corinne Thomas ◽

...

Keyword(s):

Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Patient Derived Xenograft ◽

Preclinical Efficacy ◽

Antibody Drug

Download Full-text

Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors

10.1158/1538-7445.am2017-52 ◽

2017 ◽

Author(s):

Francesca Zammarchi ◽

Halla W. Reinert ◽

Narinder Janghra ◽

Simon Corbett ◽

Maria Mellinas-Gomez ◽

...

Keyword(s):

Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors

10.1158/1538-7445.sabcs18-2688 ◽

2019 ◽

Author(s):

Sharsti L. Sandall ◽

Marsha Mason ◽

Devra Olson ◽

Rebecca Mazahreh ◽

Disha Sahetya ◽

...

Keyword(s):

Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-020-00960-z ◽

2020 ◽

Vol 38 (6) ◽

pp. 1815-1825 ◽

Cited By ~ 1

Author(s):

Charlotte Lemech ◽

Natasha Woodward ◽

Nancy Chan ◽

Joanne Mortimer ◽

Louie Naumovski ◽

...

Keyword(s):

Solid Tumors ◽

Dose Escalation ◽

Phase 1 ◽

Prolactin Receptor ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Discovery of a novel EGFR targeting antibody-drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-18-0854 ◽

2019 ◽

pp. molcanther.0854.2018

Author(s):

Kaijie He ◽

Jianyan Xu ◽

Jindong Liang ◽

Jiahua Jiang ◽

Mi Tang ◽

...

Keyword(s):

Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text